ArticleScientific reports2025
Cardiopulmonary exercise capacity markers and their link to symptom burden in patients at risk for heart failure with non-reduced ejection fraction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure.BMC cardiovascular disorders · 2026Observational
- Measuring long-term physical activity in patients with heart failure and its relation to health-related outcomes.ESC heart failure · 2026Observational
- Multimodal multi-instance learning for cardiopulmonary exercise testing performance prediction.NPJ digital medicine · 2026Article
- Altered cardiac contractility and aerobic muscular capacity markers during exercise in patients with obesity and DMT II.BMC sports science, medicine & rehabilitation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The American Heart Association (AHA) guidelines assess heart failure (HF) via comorbidities, laboratory markers, and echocardiography, while the New York Heart Association (NYHA) classification evaluates functional capacity. The primary objective of this study was to investigate the correlation between objectified HF-related symptoms and cardiac and muscular exercise capacity in Stage B HF patients with non-reduced ejection fraction. As secondary endpoints, we stratified this analysis for subgroups of NYHA classes to evaluate the primary endpoint for different levels of impairment and for sex to address for differences between men and women. Sixty-two Stage B HF patients with non-reduced EF were screened from an HF-risk cohort. Assessments included medical history, HF-related symptoms (Kansas City Cardiomyopathy Questionnaire, KCCQ), physical examination, laboratory tests, echocardiography, and cardiopulmonary exercise testing (CPET) with cardiac output monitoring. Correlations were analyzed between KCCQ score and exercise capacity markers: maximal oxygen uptake (VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.